NCT03681184View on ClinicalTrials.gov

A Study to Evaluate Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1

PHASE3CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

November 27, 2018

Primary Completion Date

November 5, 2019

Study Completion Date

January 12, 2024

Conditions
Primary Hyperoxaluria Type 1 (PH1)
Interventions
DRUG

Placebo

Placebo by SC injection

DRUG

Lumasiran

Lumasiran by SC injection

Trial Locations (17)

10029

Clinical Trial Site, New York

32216

Clinical Trial Site, Jacksonville

44195

Clinical Trial Site, Cleveland

55905

Clinical Trial Site, Rochester

92120

Clinical Trial Site, San Diego

Unknown

Clinical Trial Site, Lyon

Clinical Trial Site, Paris

Clinical Trial Site, Bonn

Clinical Trial Site, Haifa

Clinical Trial Site, Jerusalem

Clinical Trial Site, Nahariya

Clinical Trial Site, Amsterdam

Clinical Trial Site, Bern

Clinical Trial Site, Dubai

Clinical Trial Site, Birmingham

NW3 2QG

Clinical Trial Site, London

WC1N 3JH

Clinical Trial Site, London

Sponsors
All Listed Sponsors
lead

Alnylam Pharmaceuticals

INDUSTRY